- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06424262
Performances et résultats liés à l'audition chez les adultes implantés avec l'implant cochléaire à élution de dexaméthasone CI622D par rapport à ceux implantés avec un implant cochléaire standard (CI622) (DETECT)
Une enquête pivot, prospective, multicentrique, randomisée, contrôlée et en aveugle évaluant l'efficacité d'une électrode droite mince à élution de dexaméthasone (CI622D) dans la réduction de l'impédance par rapport à une électrode droite mince standard (CI622) dans une population adulte nouvellement implantée avec Surdité neurosensorielle postlinguistique, bilatérale, modérément sévère à profonde.
This clinical study will test a newly developed cochlear implant known as CI622D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation, which is common after any surgical procedure. The goal is to learn if there are added benefits in implant performance and hearing outcomes with the dexamethasone-releasing cochlear implant (CI622D) vs. the standard cochlear implant (CI622) without dexamethasone. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve. The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing ability and their overall general health.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Freiburg Im Breisgau
-
Freiburg im Breisgau, Freiburg Im Breisgau, Allemagne
- Universitätsklinikum Freiburg
-
-
Lower Saxony
-
Hanover, Lower Saxony, Allemagne
- Medizinische Hochschule Hannover
-
-
-
-
New South Wales
-
Sydney, New South Wales, Australie
- Westmead Private Hospital
-
Sydney, New South Wales, Australie
- Royal Prince Alfred Hospital
-
Sydney, New South Wales, Australie
- Macquarie University
-
-
Victoria
-
Melbourne, Victoria, Australie
- St Vincent Private Hospital
-
Melbourne E., Victoria, Australie
- Royal Victorian Eye and Ear Hospital
-
-
-
-
-
Lille, France
- Centre Hospitalier Universitaire de Lille
-
Paris, France
- Hôpital Universitaire Pitié-Salpêtrière
-
Toulouse, France
- Centre Hospitalier Universitaire Toulouse
-
-
-
-
-
Manchester, Royaume-Uni
- Manchester Royal Infirmary
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Aged 18 years or older (at time of consent)
- Clinically established post-linguistic bilateral moderately severe to profound sensorineural hearing loss
- Meets local candidacy criteria for cochlear implantation
- Compromised functional hearing with a hearing aid in the ear to be implanted
- Willing to participate in and comply with all requirements of the protocol, including willingness to be randomised to either arm
- Evidence of pneumococcal vaccination (e.g., Pneumovax) according to local guidelines prior to randomisation
- Candidate is proficient in the language used to assess speech perception performance
- Willing and able to provide written informed consent.
Exclusion Criteria:
- Planned for a partial insertion of the electrode array
- Intra-axial (within the brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted
- Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment
- Active autoimmune disease or active immunosuppressive therapy
- Any of the following in the ear to be implanted within 3 months prior to enrolment: history of prior otologic surgery including grommets, or tympanic membrane perforation
- Previously reported diagnosis of auditory neuropathy, in the ear to be implanted
- Previously reported diagnosis, in the ear to be implanted, of Large Vestibular Aqueduct Syndrome (LVAS), Meniere's disease, or cochlear hydrops
- Ossification, otosclerosis, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by imaging, in the ear to be implanted
- Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, temporo- parietal skull fracture or CSF leaks
- History of bacterial meningitis
- Known allergic reaction or contraindication to dexamethasone or corticosteroids
- Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the subject
- Severe, or poorer, sensorineural hearing loss of more than 20 years, as reported by the subject, in the ear to be implanted
- Prior cochlear implantation, in either ear
- Medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted
- Medical or psychological conditions that contraindicate general anaesthesia, surgery or participation in the clinical investigation, as determined by the investigator
- Women who are pregnant
- Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices as determined by the Investigator
- Additional disabilities that may affect the subject's participation or safety during the clinical investigation, as determined by the Investigator
- Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator
- Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as spouse, parent, child, or sibling to the study candidate
- Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation
- Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by investigator or Sponsor to not impact this investigation)
- Subjects recruited at a French site who are not affiliated with social security
- Subjects recruited at a French site who are under legal protection.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: CI622D
Investigational Medical Device (IMD) |
A dexamethasone-eluting Slim Straight electrode |
|
Comparateur actif: CI622
An approved medical device |
A standard Slim Straight electrode |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Difference in the mean impedance between CI622D and CI622
Délai: 6 months post-activation
|
Mean monopolar impedance measured across the active electrodes of the implant for each participant. |
6 months post-activation
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events of the CI622D and CI622
Délai: Throughout study (12 months)
|
Percentage of the number of participants who experience an adverse event for the CI622D group and the CI622 group |
Throughout study (12 months)
|
|
Difference in the proportion of participants with preservation of low frequency residual hearing with CI622D compared with CI622
Délai: Pre-implantation to 6 months post activation
|
The proportion of participants achieving ≤ 30 dB change in the low frequency pure tone average (LFPTA) (250 Hz and 500 Hz). This measure will be applied to the subgroup of participants who have a LFPTA < 80 dB HL at the pre-operative baseline. |
Pre-implantation to 6 months post activation
|
|
Mean change (within-subject) in word recognition score in the preferred unilateral listening mode in quiet with the CI622D
Délai: Pre-implantation to 6 months post-activation
|
Change in percent correct word recognition score |
Pre-implantation to 6 months post-activation
|
|
Mean change (within-subject) in word recognition score in the preferred bilateral listening mode in quiet with the CI622D
Délai: Pre-implantation to 6 months post-activation
|
Change in percent correct word recognition score |
Pre-implantation to 6 months post-activation
|
|
Difference in mean (within-subject) change in word recognition score in the preferred unilateral listening mode in quiet with the CI622D compared with CI622
Délai: Pre-implantation to 12 months post-activation
|
Change in percent correct word recognition score |
Pre-implantation to 12 months post-activation
|
|
Difference in mean (within-subject) change in word recognition score in the preferred bilateral listening mode in quiet from pre-implantation to post-activation with CI622D compared with CI622
Délai: Pre-implantation to 12 months post-activation
|
Change in percent correct word recognition score |
Pre-implantation to 12 months post-activation
|
|
Difference in mean (within-subject) change in sentence recognition score in noise in the preferred unilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622
Délai: Pre-implantation to 12 months post-activation
|
Change in percent correct sentence recognition score (Matrix test + 10 SNR) |
Pre-implantation to 12 months post-activation
|
|
Difference in mean (within-subject) change in sentence recognition score in noise in the preferred bilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622
Délai: Pre-implantation to 12 months post-activation
|
Change in percent correct sentence recognition score (Matrix test + 10 SNR) |
Pre-implantation to 12 months post-activation
|
|
Characterization of four-point nested impedances and monopolar impedance of the CI622D and CI622
Délai: Activation, 12 months post-activation
|
Group mean impedance measured across the active electrodes for four-point nested impedance and MP1+2 impedance for the CI622D and CI622 |
Activation, 12 months post-activation
|
|
Characterization of mean estimated sound processor battery life for CI622D and CI622
Délai: 12 months post-activation
|
The estimated sound processor battery life (hours per day) as calculated by the programming software |
12 months post-activation
|
|
Difference in mean within-subject changes in global score on the Speech, Spatial, and Qualities of Hearing Scale (SSQ12) between CI622D and CI622
Délai: Pre-implantation to 12 months post-activation
|
Speech, Spatial, and Qualities of Hearing Scale global score (SSQ-12). Scores range from 0 to 10, where higher scores indicate greater ability (less hearing disability). |
Pre-implantation to 12 months post-activation
|
|
Difference in mean within-subject changes in global Health Utilities Index III (HUI3) between CI622D and CI622
Délai: Pre-implantation to 12 months post-activation
|
Health Utilities Index (HUI 2/3) global score. Scores range from -0.36 to 1.00, where a negative score represents a state "worse than dead" and a top score of 1.00 is "perfect health". |
Pre-implantation to 12 months post-activation
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Antje Aschendorff, University Hospital Freiburg
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CLTD5815
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .